Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com
No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer
September 25th 2021Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.
Read More
Pushing the Envelope in Search of a Cure
August 29th 2021In a box, ready to be unpacked in his new office, are all the things patients have given Robert L. Coleman, MD, over the years. They include a jug of beer from a brewery in Arkansas, a golden ship from Kuwait, bottles from Serbia, art and books, and even a signed picture of Weird Al Yankovic.
Read More
Investigators Look to Enhance Response With Novel Triplet in CLL
August 5th 2021Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.
Read More
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer
June 18th 2021Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.
Read More
Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC
June 7th 2021The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.
Read More
4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC
June 4th 2021The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
Read More
Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer
May 17th 2021Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.
Read More
TIL Immunotherapy Shows Promise as Second-Line Treatment of NSCLC
May 12th 2021Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.
Read More
Shortage of Cancer Care Providers in Rural Areas Affects Patient Outcomes
May 11th 2021In the United States, a geographic mismatch exists between the number of medical oncology and radiation providers and patients needing care, with more specialists clustered in urban and metropolitan areas.
Read More
Tucatinib Combo Has Potential as Second-Line Option in HER2+ Gastric/GEJ Cancers
April 20th 2021Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.
Read More
Canadian Collaborative Launches to Provide Infrastructure for Cancer Cell Therapy Research
March 31st 2021The Canada Foundation for Innovation has awarded C$5,187,685 to the Canadian Cancer Trials Group at Queen’s University in Kingston, Ontario, Canada, to fund the infrastructure for a new research platform to coordinate the development of new cancer cell therapies.
Read More
Investigators Focus Devimistat Study on Older Patients With AML
March 15th 2021Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy
Read More
Cardio-Oncology Strategies Can Improve Survivorship for Patients With Breast Cancer
March 9th 2021Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.
Read More
New HER2-Targeting Therapies Jostle for a Place in the Treatment Lineup
March 6th 2021The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.
Read More
Investigators Aim Novel T-Cell Therapy at Solid Tumor Target
February 23rd 2021ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.
Read More
Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer
February 2nd 2021Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.
Read More